Related Experiment Video
Updated: Jul 30, 2026
04:24
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant
J A Franciosa1, W T Abraham, M Fowler
1Mount Sinai School of Medicine and Cornell University, Weill Medical College, New York, New York, USA.
Journal of Cardiac Failure
|September 21, 2000
Summary
This study observes carvedilol use in heart failure (HF) patients in real-world settings. It aims to understand how this beta-blocker performs outside of strict clinical trials for better HF management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blocking agents show success in heart failure (HF) clinical trials.
- Their performance in usual care settings is crucial for wider adoption.
- Carvedilol is the only US-approved beta-blocker for HF.
Purpose of the Study:
- To collect data on outcomes and clinical variables in a typical HF population.
- To observe the real-world experience with carvedilol in community practice.
- To assess carvedilol's performance in usual care compared to clinical trials.
Main Methods:
- The Coreg Heart Failure Registry (COHERE) is a prospective observational study.
- Approximately 6,000 patients will be enrolled by 600 community physicians.
- Patients will be followed for 1 year with data collected at multiple time points.
Main Results:
- N/A - This is a registry study design abstract.
- N/A - This is a registry study design abstract.
- N/A - This is a registry study design abstract.
Conclusions:
- COHERE is the first large prospective observational study of carvedilol in HF patients in usual care.
- The study will provide valuable information on carvedilol's effectiveness in a real-world setting.
- Findings will offer insights into HF management with carvedilol outside of clinical trials.
Related Concept Videos
01:20Study Designs in Epidemiology
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...